Oncosil Medical (OSL.AX) Stock Price

Oncosil Medical Price

ASX·CLOSED
1.21AUD-0.05 (-4.05 %)
Market closed

Revenue at Oncosil Medical has contracted by 1.0% per year over the past 19 years to 1.26 M AUD. For Oncosil Medical, the net margin of -1,196.8% is down versus -755.6% a few years ago. The consensus 12-month price target for Oncosil Medical is 0.06 AUD, about 94.9% below where the stock trades today. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 210% above its 52-week low.

Oncosil Medical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Oncosil Medical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Oncosil Medical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Oncosil Medical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Oncosil Medical Stock Price History
DateOncosil Medical Price
8/6/20261.21 AUD
8/5/20261.26 AUD
8/4/20261.22 AUD
8/3/20261.35 AUD
7/31/20261.16 AUD
7/30/20261.11 AUD
7/29/20261.11 AUD
7/28/20261.03 AUD
7/27/20261.17 AUD
7/24/20261.21 AUD
7/23/20261.30 AUD
7/22/20261.15 AUD
7/21/20261.26 AUD
7/20/20261.29 AUD
7/17/20261.45 AUD
7/16/20261.48 AUD
7/15/20261.54 AUD
7/14/20261.38 AUD
7/13/20261.41 AUD
7/10/20261.32 AUD
7/9/20261.10 AUD
7/8/20261.08 AUD
7/7/20261.05 AUD
7/6/20261.09 AUD
7/3/20260.97 AUD
7/2/20260.81 AUD
7/1/20260.75 AUD
6/30/20260.71 AUD
6/29/20260.69 AUD
6/26/20260.68 AUD
6/25/20260.58 AUD
6/24/20260.62 AUD
6/23/20260.59 AUD
6/22/20260.64 AUD
6/19/20260.80 AUD
6/18/20260.59 AUD
6/17/20260.57 AUD
6/16/20260.57 AUD
6/15/20260.59 AUD
6/12/20260.56 AUD
6/11/20260.52 AUD
6/10/20260.57 AUD
6/9/20260.57 AUD
6/5/20260.44 AUD
6/4/20260.44 AUD
6/3/20260.44 AUD
6/2/20260.46 AUD
6/1/20260.49 AUD
5/29/20260.51 AUD
5/28/20260.49 AUD
5/27/20260.50 AUD
5/26/20260.50 AUD
5/25/20260.52 AUD
5/22/20260.51 AUD
5/21/20260.51 AUD
5/20/20260.52 AUD
5/19/20260.39 AUD
5/18/20260.40 AUD
5/15/20260.45 AUD
5/14/20260.45 AUD
5/13/20260.49 AUD
5/12/20260.47 AUD
5/11/20260.50 AUD
5/8/20260.51 AUD
5/7/20260.50 AUD
5/6/20260.50 AUD
5/5/20260.50 AUD
5/4/20260.51 AUD
5/1/20260.51 AUD
4/30/20260.49 AUD
4/29/20260.49 AUD
4/28/20260.52 AUD
4/27/20260.49 AUD
4/24/20260.49 AUD
4/23/20260.48 AUD
4/22/20260.51 AUD
4/21/20260.51 AUD
4/20/20260.51 AUD
4/17/20260.49 AUD
4/16/20260.50 AUD
4/15/20260.50 AUD
4/14/20260.50 AUD
4/13/20260.51 AUD
4/10/20260.51 AUD
4/9/20260.51 AUD
4/8/20260.50 AUD
4/7/20260.50 AUD
4/2/20260.52 AUD
4/1/20260.51 AUD
3/31/20260.50 AUD
3/30/20260.50 AUD
3/27/20260.51 AUD
3/26/20260.51 AUD
3/25/20260.52 AUD
3/24/20260.50 AUD
3/23/20260.49 AUD
3/20/20260.49 AUD
3/19/20260.47 AUD
3/18/20260.52 AUD
3/17/20260.55 AUD
3/16/20260.55 AUD
3/13/20260.56 AUD
3/12/20260.57 AUD
3/11/20260.57 AUD
3/10/20260.60 AUD
3/9/20260.62 AUD
3/6/20260.63 AUD
3/5/20260.63 AUD
3/4/20260.63 AUD
3/3/20260.64 AUD
3/2/20260.65 AUD
2/27/20260.65 AUD
2/26/20260.65 AUD
2/25/20260.65 AUD
2/24/20260.66 AUD
2/23/20260.65 AUD
2/20/20260.65 AUD
2/19/20260.68 AUD
2/18/20260.66 AUD
2/17/20260.65 AUD
2/16/20260.68 AUD
2/13/20260.68 AUD
2/12/20260.69 AUD
2/11/20260.70 AUD
2/10/20260.72 AUD
2/9/20260.68 AUD
2/6/20260.68 AUD
2/5/20260.72 AUD
2/4/20260.71 AUD
2/3/20260.70 AUD
2/2/20260.80 AUD
1/30/20260.80 AUD
1/29/20260.80 AUD
1/28/20260.83 AUD
1/27/20260.84 AUD
1/23/20260.76 AUD
1/22/20260.79 AUD
1/21/20260.85 AUD
1/20/20260.91 AUD
1/19/20260.92 AUD
1/16/20260.93 AUD
1/15/20260.92 AUD
1/14/20260.91 AUD
1/13/20260.86 AUD
1/12/20260.87 AUD
1/9/20260.93 AUD
1/8/20260.86 AUD
1/7/20260.86 AUD
1/6/20260.90 AUD
1/5/20260.90 AUD
1/2/20260.97 AUD
12/31/20250.97 AUD
12/30/20250.98 AUD
12/29/20250.96 AUD
12/24/20251.01 AUD
12/23/20251.04 AUD
12/22/20251.05 AUD
12/19/20251.04 AUD
12/18/20251.04 AUD
12/17/20251.04 AUD
12/16/20251.10 AUD
12/15/20251.04 AUD
12/12/20251.05 AUD
12/11/20251.09 AUD
12/10/20251.01 AUD
12/9/20251.02 AUD
12/8/20251.05 AUD
12/5/20251.10 AUD
12/4/20251.09 AUD
12/3/20251.12 AUD
12/2/20251.13 AUD
12/1/20251.11 AUD
11/28/20251.07 AUD
11/27/20251.07 AUD
11/26/20251.14 AUD
11/25/20251.15 AUD
11/24/20251.16 AUD
11/21/20251.16 AUD
11/20/20251.16 AUD
11/19/20251.15 AUD
11/18/20251.20 AUD
11/17/20251.14 AUD
11/14/20251.25 AUD
11/13/20251.31 AUD
11/12/20251.31 AUD
11/11/20251.35 AUD
11/10/20251.26 AUD
11/7/20251.31 AUD
11/6/20251.31 AUD
11/5/20251.35 AUD
11/4/20251.32 AUD
11/3/20251.27 AUD
10/31/20251.25 AUD
10/30/20251.35 AUD
10/29/20251.50 AUD
10/28/20251.50 AUD
10/27/20251.50 AUD
10/24/20251.54 AUD
10/23/20251.46 AUD
10/22/20251.55 AUD
10/21/20251.64 AUD
10/20/20251.68 AUD
10/17/20251.70 AUD
10/16/20251.68 AUD
10/15/20251.68 AUD
10/14/20251.66 AUD
10/13/20251.67 AUD
10/10/20251.73 AUD
10/9/20251.70 AUD
10/8/20251.70 AUD
10/7/20251.70 AUD
10/6/20251.71 AUD
10/3/20251.77 AUD
10/2/20251.66 AUD
10/1/20251.73 AUD
9/30/20251.66 AUD
9/29/20251.67 AUD
9/26/20251.65 AUD
9/25/20251.65 AUD
9/24/20251.73 AUD
9/23/20251.65 AUD
9/22/20251.70 AUD
9/19/20251.99 AUD
9/18/20251.90 AUD
9/17/20251.64 AUD
9/16/20251.64 AUD
9/15/20251.60 AUD
9/12/20251.67 AUD
9/11/20251.72 AUD
9/10/20251.65 AUD
9/9/20251.60 AUD
9/8/20251.24 AUD
9/5/20251.21 AUD
9/4/20251.12 AUD
9/3/20251.12 AUD
9/2/20251.12 AUD
9/1/20251.14 AUD
8/29/20251.14 AUD
8/28/20251.15 AUD
8/27/20251.12 AUD
8/26/20251.09 AUD
8/25/20251.09 AUD
8/22/20251.09 AUD
8/21/20251.09 AUD
8/20/20251.12 AUD
8/19/20251.13 AUD
8/18/20251.16 AUD
8/15/20251.13 AUD
8/14/20251.12 AUD
8/13/20251.20 AUD
8/12/20251.20 AUD
8/11/20251.10 AUD
Access this data via the Eulerpool API
Get Free API Key

Oncosil Medical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
2.87 M AUD
-4.34 M AUD
-4.26 M AUD
Jan 1, 2021
1.38 M AUD
-10.46 M AUD
-10.43 M AUD
Jan 1, 2022
1.07 M AUD
-10.57 M AUD
-10.73 M AUD
Jan 1, 2023
430,300.00 AUD
-11.27 M AUD
-11.34 M AUD
Jan 1, 2024
583,200.00 AUD
-11.92 M AUD
-11.91 M AUD
Jan 1, 2025
1.26 M AUD
-15.00 M AUD
-15.10 M AUD
Jan 1, 2026 (e)
34.60 M AUD
-9.32 M AUD
-130,240.08 AUD
Jan 1, 2027 (e)
60.50 M AUD
0.00 AUD
0.00 AUD

Oncosil Medical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 9, 2026, 10:46 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEk AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
–––3.004.003.004.003.002.001.001.00––1.0034.0060.00
––––33.33-25.0033.33-25.00-33.33-50.00––––3,300.0076.47
–––-33.33-25.00-33.33-25.00-33.33-50.00-100.00-100.00––-100.00-2.94-1.67
-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00-1,000.00
––-4.00-2.00-4.00-7.00-8.00-8.00-4.00-10.00-10.00-11.00-11.00-14.00-9.00–
–––-66.67-100.00-233.33-200.00-266.67-200.00-1,000.00-1,000.00––-1,400.00-26.47–
––-4.00-2.00-4.00-7.00-8.00-8.00-4.00-10.00-10.00-11.00-11.00-15.00––
–––-50.00100.0075.0014.29–-50.00150.00–10.00–36.36––
0.330.421.651.201.301.581.732.112.162.702.642.995.5510.9310.9310.93
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Oncosil Medical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Oncosil Medical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Oncosil Medical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Oncosil Medical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Oncosil Medical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Oncosil Medical stock margins

The Oncosil Medical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncosil Medical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncosil Medical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
-78.62 %
-151.32 %
-148.57 %
Jan 1, 2021
30.40 %
-757.49 %
-755.61 %
Jan 1, 2022
9.42 %
-984.41 %
-999.23 %
Jan 1, 2023
-269.23 %
-2,619.78 %
-2,636.04 %
Jan 1, 2024
-158.88 %
-2,043.48 %
-2,042.80 %
Jan 1, 2025
-78.62 %
-1,188.69 %
-1,196.78 %
Jan 1, 2026 (e)
-78.62 %
-26.92 %
-0.38 %
Jan 1, 2027 (e)
-78.62 %
0.00 %
0.00 %

Oncosil Medical Stock Revenue, EBIT, Earnings per Share

The Oncosil Medical earnings per share therefore indicates how much revenue Oncosil Medical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
1.33 AUD
-2.01 AUD
-1.97 AUD
Jan 1, 2021
0.51 AUD
-3.88 AUD
-3.87 AUD
Jan 1, 2022
0.41 AUD
-4.00 AUD
-4.06 AUD
Jan 1, 2023
0.14 AUD
-3.77 AUD
-3.79 AUD
Jan 1, 2024
0.11 AUD
-2.15 AUD
-2.15 AUD
Jan 1, 2025
0.12 AUD
-1.37 AUD
-1.38 AUD
Jan 1, 2026 (e)
3.17 AUD
-0.85 AUD
-0.01 AUD
Jan 1, 2027 (e)
5.54 AUD
0.00 AUD
0.00 AUD

Oncosil Medical business model & stock analysis

Oncosil Medical Ltd is an Australian company specializing in the development and distribution of innovative medical products for the treatment of cancer. The company was founded in 2005 and is based in Sydney. The business model of Oncosil Medical is based on research, development, and marketing of products specifically tailored to the needs of cancer patients. The company focuses on developing medical products that aim to improve the effectiveness of radiation therapy and chemotherapy. The core product of Oncosil Medical is the Oncosil implant. It is a small, implantable catheter containing tiny radioactive silicon particles. The implant is directly inserted into the tumor and releases controlled radiation to specifically destroy the tumor. The Oncosil implant is a promising and innovative new treatment option for many cancer patients. It is particularly suitable for patients with locally advanced pancreatic cancer, which is especially difficult to treat. Studies have shown that the Oncosil implant can significantly improve patients' survival rate. Oncosil Medical also provides other products, such as the Microsil transponder. The Microsil transponder is a small implant used in radiation therapy to make the irradiation of the tumor more effective. The transponder is directly inserted into the tumor, allowing medical professionals to precisely target the radiation to the tumor. In addition to developing and marketing innovative medical products, Oncosil Medical also has a research and development department. The company is constantly searching for new cancer treatment methods and works closely with scientists and researchers to develop new technologies. Oncosil Medical operates in several areas. In addition to developing and marketing medical products, the company also offers a training and education program for doctors and medical personnel. The program ensures that all users of Oncosil Medical's products have the necessary skills and knowledge to use the products safely and effectively. The company also has its own regulatory affairs department, which deals with the application for approvals for new products and procedures. This department works closely with authorities and regulatory agencies to ensure that all products from Oncosil Medical comply with applicable regulations and standards. Overall, Oncosil Medical is an innovative and emerging company specializing in the development and marketing of medical products for cancer treatment. With its highly skilled team of scientists, doctors, and qualified professionals, the company stays up to date with the latest research and technology to ensure that its products are always state-of-the-art and provide customers with the best possible treatment option.

Oncosil Medical SWOT Analysis

Strengths

Oncosil Medical Ltd has a proprietary medical technology that has shown potential in treating various types of solid tumors.

The company has a strong intellectual property portfolio, including patents and trademarks, which provides a competitive advantage.

Oncosil has a dedicated and experienced team of researchers and medical professionals who are committed to advancing the field of oncology.

Weaknesses

The company is currently in the early stages of development and has not yet commercialized its technology, which creates financial uncertainties.

Oncosil Medical Ltd heavily relies on external funding to support its research and development efforts, making it vulnerable to market fluctuations.

The regulatory approval process for medical devices and treatments can be lengthy and costly, posing potential delays and obstacles for the company.

Opportunities

The global oncology market is experiencing significant growth, driven by increasing cancer rates and advancements in medical technology, presenting a favorable market environment for Oncosil.

Partnerships and collaborations with established pharmaceutical companies can provide access to additional resources and accelerate the commercialization process.

Expansion into international markets, particularly regions with high cancer prevalence, offers the potential for increased revenue and market share.

Threats

Competition in the oncology space is intense, with numerous established companies and startups vying for market share.

Changes in healthcare regulations and reimbursement policies may impact the adoption and pricing of Oncosil's technology.

Failure to meet clinical trial endpoints or demonstrate the efficacy and safety of its products could hinder regulatory approvals and market acceptance.

Oncosil Medical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Oncosil Medical historical P/E ratio, EBIT multiple, and P/S ratio

Oncosil Medical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Oncosil Medical shares outstanding

The number of shares of Oncosil Medical was 10.93 M in 2025. This indicates how many shares Oncosil Medical is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
2.16 M Stocks
Jan 1, 2021
2.70 M Stocks
Jan 1, 2022
2.64 M Stocks
Jan 1, 2023
2.99 M Stocks
Jan 1, 2024
5.55 M Stocks
Jan 1, 2025
10.93 M Stocks
Jan 1, 2026 (e)
10.93 M Stocks
Jan 1, 2027 (e)
10.93 M Stocks

Oncosil Medical stock splits

In Oncosil Medical's history, there have been no stock splits.

Current Oncosil Medical forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
42.86 % (3)
Sell
57.14 % (4)
12M Price Target
0.06
Last Price
1.25
Currency
AUD
12M Return Potential
-95.08 %
LTM Return
0 %

Oncosil Medical shareholder structure

% Name
31.31886%
Pengana Capital Group Limited
Pengana Capital Group Limited
11.93665%
Australian Ethical Investment Ltd.
Australian Ethical Investment Ltd.

Oncosil Medical Executives and Management Board

6 members · 17 % women

NL

Mr. Nigel Lange

Chief Executive Officer, Managing Director, Executive Director · since 2021

608,489.00 AUD

Management

CC

Mr. Christian Cin

Chief Financial Officer, Company Secretary

–

Board of Directors

DC

Mr. Douglas Cubbin

Non-Executive Chairman of the Board

–
PH

Mr. Peter Hall

Non-Executive Director

–
GL

Mr. Gabriel Liberatore

Non-Executive Director

–
LS

Ms. Lelde Smits

Non-Executive Director

–

Oncosil Medical Supply Chain

Oncosil Medical Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
EyePoint Pharmaceuticals
Supplier·Customer·Pharmaceuticals·US
0.26
-0.30
-0.04
0.13
-0.40
-0.69

Frequently asked questions about Oncosil Medical

The business model of Oncosil Medical Ltd focuses on developing and commercializing innovative medical devices for the treatment of various cancers. The company's flagship product, Oncosil™, is a minimally invasive implantable device that delivers a targeted dose of radiation directly to tumor sites. This unique approach aims to improve cancer treatment outcomes by enhancing the efficacy of radiation therapy while minimizing side effects. Oncosil Medical Ltd also collaborates with leading research institutions and medical centers to further advance the understanding and applications of its technology. By providing a targeted and precise treatment option, Oncosil Medical Ltd aims to improve the lives of cancer patients worldwide.

Oncosil Medical Ltd is primarily active in the healthcare industry.

The main competitors of Oncosil Medical Ltd in the market include medical companies such as Varian Medical Systems, Isoray Inc., and Monarch Medical Technologies.

Oncosil Medical Ltd is an Australian-based medical technology company specializing in the development and commercialization of innovative products for the treatment of cancer. Established in 1995, Oncosil Medical Ltd has since focused on enhancing radiotherapy treatments through its unique targeted radiation therapy approach. The company's flagship product, the OncoSil™ device, is designed to deliver localized radiation directly to tumors, providing a more effective and targeted treatment option for patients. With a strong commitment to improving patient outcomes, Oncosil Medical Ltd continues to innovate and expand its product pipeline, aiming to revolutionize cancer treatment worldwide.

Oncosil Medical Ltd has achieved several significant milestones. Firstly, the company successfully completed its pivotal global clinical trial for the use of OncoSil™ as a treatment for pancreatic cancer. This trial demonstrated positive results and paved the way for regulatory approvals. Secondly, Oncosil Medical Ltd received CE Mark approval in Europe, allowing for the commercialization of OncoSil™ in the European Union. Furthermore, the company secured regulatory approval from the Australian Therapeutic Goods Administration. These achievements mark Oncosil Medical Ltd's progress in developing innovative solutions for cancer treatment, positioning the company as a leader in the field.

Oncosil Medical Ltd is primarily present in Australia.

Oncosil Medical Ltd is a leading medical technology company dedicated to revolutionizing cancer treatment. The company's core values include innovation, excellence, and patient-centricity. Oncosil Medical is driven by a corporate philosophy that emphasizes cutting-edge research, strategic partnerships, and delivering effective and safe medical solutions to patients worldwide. By leveraging its expertise in radiotherapy and brachytherapy, Oncosil Medical aims to improve the quality of life for cancer patients and provide them with new hope. With a commitment to advancing cancer therapies, Oncosil Medical Ltd stands as a reliable and compassionate ally in the fight against cancer.

Analysts currently set an average price target of 0.06 AUD for the Oncosil Medical stock (median: 0.06 AUD), implying -95.1 % versus the latest price. The consensus is based on 7 analyst ratings.

Oncosil Medical Analyst Price Targets 2026

7 analysts currently rate the Oncosil Medical stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect Oncosil Medical to generate revenue of 34.60 M AUD and earnings per share of -0.01 AUD.

Oncosil Medical Analyst Price Targets 2026

Converted at the current exchange rate, the Oncosil Medical share trades at 0.74 EUR (1.21 AUD).

The Oncosil Medical share (OSL.AX) is listed on 1 stock exchanges, including: ASX (OSL.AX).

Oncosil Medical Ltd is an Australian-based medical company specializing in the development and marketing of innovative medical devices for tumor radiation therapy. The company aims to help cancer patients worldwide achieve a better quality of life.

The expected revenue of Oncosil Medical is 34.60 M AUD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Oncosil Medical is -130,240.08 AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Oncosil Medical is currently -101.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Oncosil Medical stock.

The price-to-sales ratio (P/S) of Oncosil Medical is currently 0.38. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Oncosil Medical stock.

The Eulerpool Quality Score for Oncosil Medical is 3/10.

The ISIN of Oncosil Medical is AU000000OSL3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Oncosil Medical is A1WZU4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Oncosil Medical is OSL.AX. The ticker symbol is used to trade Oncosil Medical shares on the stock exchange.

Oncosil Medical paid dividends every year for the past 0 years.

Oncosil Medical is assigned to the 'Health' sector.

The dividends of Oncosil Medical are distributed in AUD.

All fundamentals and in-depth analysis of Oncosil Medical

Our stock analysis for Oncosil Medical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncosil Medical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Oncosil Medical Stock
Oncosil Medical Revenue→
Oncosil Medical Stock
Oncosil Medical Net Income→
Oncosil Medical Stock
Oncosil Medical P/E→
Oncosil Medical Stock
Oncosil Medical P/S→
Oncosil Medical Stock
Oncosil Medical EBIT→
Oncosil Medical Stock
Oncosil Medical Dividend→
Oncosil Medical Stock
Oncosil Medical Directors Dealings→
Oncosil Medical Stock
Oncosil Medical Stocks→
Oncosil Medical Stock
Oncosil Medical Market capitalization→
Oncosil Medical Stock
Oncosil Medical Debt→
Oncosil Medical Stock
Oncosil Medical Liabilities→
Oncosil Medical Stock
Oncosil Medical Equity→
Oncosil Medical Stock
Oncosil Medical AAQS→
Oncosil Medical Stock
Oncosil Medical Employees→
Oncosil Medical Stock
Oncosil Medical ROE→
Oncosil Medical Stock
Oncosil Medical ROA→
Oncosil Medical Stock
Oncosil Medical ROCE→
Oncosil Medical Stock
Oncosil Medical News→
Oncosil Medical Stock
Oncosil Medical Analyst Price Targets→

Health Stocks

Oncotelic TherapeuticsOncoSec MedicalOncoTherapy ScienceOncopeptidesOncovista Innovative TherapiesOnconova TherapeuticsOncozengeOnconetixOndine BiomedicalOncolytics BiotechOne Health GroupOncolys BiopharmaAll Stocks A–Z →